Hypertension as a risk factor for hip fracture

Pérez‐Castrillón, José Luis; Martı́n-Escudero, Juan Carlos; Manzanares, Paloma; Sancho, R. Cortés; Zamora, S. Iglesias; Alonso, Manuel García

doi:10.1016/j.amjhyper.2004.08.016

Cited by 35 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When the analyses were limited to the age group [50 years, the results did not change [13]. Similarly, another case-control study conducted in Spain involving elderly subjects aged [65 years with 996 cases and 3005 controls found that hypertension increased the risk of hip fractures (OR 1.45, 95 % CI 1.2-1.7) [14]. A prospective cohort study of 31,936 Swedish twins aged C50 years where 8506 individual twins had hypertension found that there was an increased risk of hip fracture in hypertensive twins (hazard ratio, HR 1.59, 95 % CI 1.36-1.85) although this finding was not the main outcome of the study [17].…”

Section: Hypertension and Fracture Riskmentioning

confidence: 78%

“…Clinical studies generally support an increased risk of fractures in patients with hypertension [13][14][15][16][17]. Plausible mechanisms for the effect of hypertension on bone exist.…”

Section: Hypertension and Fracture Riskmentioning

confidence: 96%

“…Table 3 provides a summary of the studies examining the effect of ACE inhibitors and ARBs on fracture risk. A case-control study conducted in Spain demonstrated an increased risk of hip fractures in both women and men on ACE inhibitors compared to nonusers in an unadjusted analysis [14]. A cohort study conducted in South Korea over a 1.6-year period indicated that new users of ACE inhibitors had an increased fracture risk (HR 1.68, 95 % CI 1.49-1.91), while new users of ARBs did not (HR 1.00, 95 % CI 0.95-1.05), compared to nonusers [41].…”

Section: Renin-angiotensin System (Ace Inhibitors and Arbs) And Fractmentioning

confidence: 99%

See 2 more Smart Citations

Hypertension, Antihypertensive Drugs and the Risk of Fractures

Butt

Alharty

Leu

et al. 2015

Clinic Rev Bone Miner Metab

View full text Add to dashboard Cite

Older adults have a higher prevalence of hypertension, and specifically systolic hypertension, than any other age group in the general population as the likelihood of developing hypertension during an average lifespan is high. Osteoporosis like hypertension is a chronic medical condition that can predispose the elderly to increased fracture risk. The relationship between hypertension, antihypertensive medications and osteoporosisrelated fractures is complex as hypertension and the medications used to treat hypertension such as thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers and beta-adrenergic blockers may have differential effects on bone. The purpose of this review is to provide an overview of the relationship between hypertension and bone and to examine the association between different antihypertensive medications on fracture risk in the elderly.

show abstract

Section: Hypertension and Fracture Riskmentioning

confidence: 78%

“…Clinical studies generally support an increased risk of fractures in patients with hypertension [13][14][15][16][17]. Plausible mechanisms for the effect of hypertension on bone exist.…”

Section: Hypertension and Fracture Riskmentioning

confidence: 96%

Section: Renin-angiotensin System (Ace Inhibitors and Arbs) And Fractmentioning

confidence: 99%

See 1 more Smart Citation

Hypertension, Antihypertensive Drugs and the Risk of Fractures

Butt

Alharty

Leu

et al. 2015

Clinic Rev Bone Miner Metab

View full text Add to dashboard Cite

show abstract

“…These alterations include a decrease in ionic calcium, an increase in calciuria and cyclic adenosine 5 -monophosphate, and increases in parathyroid hormone (PTH) serum concentration, calcitriol in plasma and calcium intestinal absorption [4,5] . Moreover, hypertension may be a risk factor for hip fracture in women [6] .…”

Section: Introductionmentioning

confidence: 99%

Ghrelin and Bone Mass in Postmenopausal Hypertensive Women

Pérez‐Castrillón¹,

Justo²,

Sanz³

et al. 2007

Ann Nutr Metab

View full text Add to dashboard Cite

Background: Ghrelin, a recently discovered peptide mainly secreted by the stomach, has an orexigenic effect which stimulates secretion of the growth hormone. It also has vasodilator effects which reduce blood pressure and stimulate in vitro, bone formation. Objectives: To evaluate the effect of ghrelin on bone mass and bone remodeling markers in postmenopausal hypertensive women. Material and Methods: 25 postmenopausal hypertensive women, light to moderate based on the JNC-VII criteria, were studied. They had a mean age of 58 ± 8 years, a body mass index of 28 ± 6 and a hypertension development time of 65 ± 84 months. Osteocalcin, PTHi, 25-vitamin D, ghrelin in serum and deoxypiridinoline in urine were determined in all patients. A lumbar spine densitometer was made (DXP Lunar, Madison, Wisc., USA). Results: Diminished levels of ghrelin were observed in the osteoporotic group (40 ± 19 vs. 78 ± 40, p = 0.027). When the patients were separated according to ghrelin tertiles, a greater bone mass was observed in the upper tertiles, which was associated with a decrease in the urinary deoxypiridinoline. When the total population was analyzed, no relation between the ghrelin and bone mass was found, nor with any of the parameters of calcium metabolism. Only a statistically significant relation between ghrelin and deoxypiridinoline was observed (r = –0.428, p = 0.026). Conclusions: In postmenopausal hypertensive women, ghrelin may produce a protecting effect over bone mass through an anticatabolic mechanism manifested by a decrease of bone resorption.

show abstract

“…Recent studies suggest that AHT is a risk factor for the appearance of pathological fractures 1,2 . Thus, in patients with hypertension various alterations in the metabolism of calcium have been described, such as an increase in ionic calcium and an increase in PTH and calciuria, although only this last change has been associated with an increase in bone mass [3][4][5] .…”

Section: Introductionmentioning

confidence: 99%

Polimorfismo A986S del receptor sensor del calcio y fracturas clínicas osteoporóticas

Abad-Manteca

Cuadrado-Medina

et al. 2015

Rev Osteoporos Metab Miner

View full text Add to dashboard Cite

Summary Introduction:The relationship between osteoporosis and arterial hypertension has not been clearly established, with alterations in calcium metabolism having been reported in the latter which may explain their association. Our objective was to establish the relationship between the A986S polymorphism of the calcium-sensing receptor (CaSR) and the presence of osteoporotic clinical fractures in a group of patients with hypertension. Material: Prospective observational cohort study in 71 patients with hypertension, from 2001 to June 2014. We obtained socio-demographic and clinical data, including osteoporotic clinical fractures. The CaSR polymorphism was analysed using molecular techniques. The data was analysed using SPSS 15.0 (p<0.5) Results: 43.77% of the patients were men and 56.3% women. Genotype AA was found in 67.6% of patients, genotype SS in 2.8% and genotype AS in 29.6%. Those with genotype AA did not have higher comorbidity (27% vs 26%, p=0.9) or more pathological fractures (14.6% vs 21.7%, p=0.4) than the others. In the subgroup of women, 11 osteoporotic clinical fractures were recorded, without there being any differences between those with the AA genotype and the others (28% vs 27%, p=0.9). Conclusions: We found no association between the A986S polymorphism and the presence of osteoporotic clinical fractures in our cohort.

show abstract

Hypertension as a risk factor for hip fracture

Cited by 35 publications

References 6 publications

Hypertension, Antihypertensive Drugs and the Risk of Fractures

Hypertension, Antihypertensive Drugs and the Risk of Fractures

Ghrelin and Bone Mass in Postmenopausal Hypertensive Women

Polimorfismo A986S del receptor sensor del calcio y fracturas clínicas osteoporóticas

Contact Info

Product

Resources

About